title: [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
abstract: This study was undertaken to determine the clinical usefulness of NMP22 (Nuclear Matrix Protein 22) as a urinary marker for the screening of urothelial cancer in patients with microscopic hematuria, especially in comparison with that of voided urine cytology. Urinary NMP22 values were determined for 183 patients with microscopic hematuria by use of a UNMP22 Test kit, which is based on an enzyme-linked immunosorbent assay. All patients were entered in this study before cystoscopy was performed, and were evaluated for NMP22 values and voided urine cytology simultaneously from the same urine samples. Of the 183 patients with microscopic hematuria, 14 cases of urothelial cancer were detected. For the other cases, 65 were of benign diseases and 104 were designated NED (No Evidence of Disease). The median NMP22 values for urothelial cancer, benign diseases, and NED were 26.5 U/ml (95% CI: 18.5-228.2; 4.9 U/ml (95% CI: 3.6-8.3), and 5.9 U/ml (95% CI: 4.8-6.5), respectively. The urinary NMP22 value for urothelial cancer was significantly higher than for benign diseases and NED. When the cut-off value of urinary NMP22 was set at 12 U/ml, the positive rate of NMP22 for urothelial cancer was 85.7%, significantly higher than the 50% positive rate by voided urine cytology. This study indicates that urinary NMP22 is a useful tool for the screening of urothelial cancer in patients with microscopic hematuria.
authors.affiliation: Dept. of Urology, University of Tsukuba.
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: N
authors.initials: N
authors.lastname: Miyanaga
authors.forename: T
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: R
authors.initials: R
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Ohtani
authors.forename: K
authors.initials: K
authors.lastname: Kawabe
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Obata
authors.forename: Y
authors.initials: Y
authors.lastname: Hirao
authors.forename: T
authors.initials: T
authors.lastname: Kotake
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
authors.forename: J
authors.initials: J
authors.lastname: Kumazawa
authors.forename: K
authors.initials: K
authors.lastname: Koiso
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis*; D005260:Female; D006417:Hematuria / Q000652:urine*; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000652:urine*; D012680:Sensitivity and Specificity; D014523:Urethral Neoplasms / Q000175:diagnosis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis*
chemical_list: D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22